Immuneering (IMRX) Cash & Equivalents (2020 - 2024)
Historic Cash & Equivalents for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to $45.2 million.
- Immuneering's Cash & Equivalents fell 3356.06% to $45.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $45.2 million, marking a year-over-year decrease of 3356.06%. This contributed to the annual value of $59.4 million for FY2023, which is 1821.54% down from last year.
- According to the latest figures from Q3 2024, Immuneering's Cash & Equivalents is $45.2 million, which was down 3356.06% from $59.7 million recorded in Q2 2024.
- Immuneering's 5-year Cash & Equivalents high stood at $106.9 million for Q3 2021, and its period low was $37.1 million during Q4 2020.
- For the 5-year period, Immuneering's Cash & Equivalents averaged around $70.8 million, with its median value being $72.6 million (2022).
- Per our database at Business Quant, Immuneering's Cash & Equivalents skyrocketed by 10190.84% in 2021 and then plummeted by 4257.85% in 2024.
- Over the past 5 years, Immuneering's Cash & Equivalents (Quarter) stood at $37.1 million in 2020, then skyrocketed by 101.91% to $74.9 million in 2021, then dropped by 3.01% to $72.6 million in 2022, then decreased by 18.22% to $59.4 million in 2023, then dropped by 23.9% to $45.2 million in 2024.
- Its last three reported values are $45.2 million in Q3 2024, $59.7 million for Q2 2024, and $66.3 million during Q1 2024.